These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 11323011)

  • 1. Detection of soluble urokinase receptor by immunoradiometric assay and its application in tumor patients.
    Gao W; Wang Z; Bai X; Xi X; Ruan C
    Thromb Res; 2001 Apr; 102(1):25-31. PubMed ID: 11323011
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of soluble urokinase plasminogen activator receptor may be related to outcome in prostate cancer patients.
    McCabe NP; Angwafo FF; Zaher A; Selman SH; Kouinche A; Jankun J
    Oncol Rep; 2000; 7(4):879-82. PubMed ID: 10854562
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma urokinase receptor levels in patients with colorectal cancer: relationship to prognosis.
    Stephens RW; Nielsen HJ; Christensen IJ; Thorlacius-Ussing O; Sørensen S; Danø K; Brünner N
    J Natl Cancer Inst; 1999 May; 91(10):869-74. PubMed ID: 10340907
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The level of urokinase-type plasminogen activator receptor is increased in serum of ovarian cancer patients.
    Sier CF; Stephens R; Bizik J; Mariani A; Bassan M; Pedersen N; Frigerio L; Ferrari A; Danø K; Brünner N; Blasi F
    Cancer Res; 1998 May; 58(9):1843-9. PubMed ID: 9581823
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Soluble urokinase plasminogen activator receptor in plasma of patients with inflammatory rheumatic disorders: increased concentrations in rheumatoid arthritis.
    Slot O; Brünner N; Locht H; Oxholm P; Stephens RW
    Ann Rheum Dis; 1999 Aug; 58(8):488-92. PubMed ID: 10419867
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monitoring of chemotherapy successfulness of platina/taxol chemotherapy protocol by using determination of serum urokinase plasminogen activator (uPA) and soluble urokinase plasminogen activator receptor (suPAR) in patients with ovarian carcinoma FIGO II and III stage.
    Ljuca D; Fatusić Z; Iljazović E; Ahmetović B
    Bosn J Basic Med Sci; 2007 May; 7(2):111-6. PubMed ID: 17489744
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Urokinase plasminogen activator receptor and soluble matrix metalloproteinase-9 in acute myeloid leukemia patients: a possible relation to disease invasion.
    Aref S; El-Sherbiny M; Mabed M; Menessy A; El-Refaei M
    Hematology; 2003 Dec; 8(6):385-91. PubMed ID: 14668033
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ELISA determination of soluble urokinase receptor in blood from healthy donors and cancer patients.
    Stephens RW; Pedersen AN; Nielsen HJ; Hamers MJ; Høyer-Hansen G; Rønne E; Dybkjaer E; Danø K; Brünner N
    Clin Chem; 1997 Oct; 43(10):1868-76. PubMed ID: 9342006
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The prognostic value of plasma soluble urokinase plasminogen activator receptor (suPAR) levels in stage III ovarian cancer patients.
    Begum FD; Høgdall CK; Kjaer SK; Christensen L; Blaakaer J; Bock JE; Glud E; Høyer-Hansen G; Ring-Larsen H; Høgdall EV
    Anticancer Res; 2004; 24(3b):1981-5. PubMed ID: 15274388
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Diagnostic significance of measurement of the receptor for urokinase-type plasminogen activator on granulocytes and in plasma from patients with paroxysmal nocturnal hemoglobinuria].
    Gao W; Wang Z; Zhou Y
    Zhonghua Nei Ke Za Zhi; 2001 Nov; 40(11):740-3. PubMed ID: 11930678
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Soluble urokinase receptor levels correlate with number of circulating tumor cells in acute myeloid leukemia and decrease rapidly during chemotherapy.
    Mustjoki S; Sidenius N; Sier CF; Blasi F; Elonen E; Alitalo R; Vaheri A
    Cancer Res; 2000 Dec; 60(24):7126-32. PubMed ID: 11156421
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic significance of soluble urokinase plasminogen activator receptor in serum and cytosol of tumor tissue from patients with primary breast cancer.
    Riisbro R; Christensen IJ; Piironen T; Greenall M; Larsen B; Stephens RW; Han C; Høyer-Hansen G; Smith K; Brünner N; Harris AL
    Clin Cancer Res; 2002 May; 8(5):1132-41. PubMed ID: 12006529
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elevated soluble urokinase plasminogen activator receptor in plasma from patients with idiopathic myelofibrosis or polycythaemia vera.
    Jensen MK; Riisbro R; de Nully Brown P; Brünner N; Hasselbalch HC
    Eur J Haematol; 2002 Jul; 69(1):43-9. PubMed ID: 12270061
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Soluble urokinase plasminogen activator receptor in preoperatively obtained plasma from patients with gynecological cancer or benign gynecological diseases.
    Riisbro R; Stephens RW; Brünner N; Christensen IJ; Nielsen HJ; Heilmann L; von Tempelhoff GF
    Gynecol Oncol; 2001 Sep; 82(3):523-31. PubMed ID: 11520150
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New ELISA for quantitation of human urokinase receptor (CD87) in cancer.
    Kotzsch M; Luther T; Harbeck N; Ockert D; Lutz V; Noack F; Grossmann D; Albrecht S; Kramer MD; Lossnitzer A; Grosser M; Schmitt M; Magdolen V
    Int J Oncol; 2000 Oct; 17(4):827-34. PubMed ID: 10995898
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Soluble urokinase receptor (uPAR, CD 87) is present in serum and cerebrospinal fluid in patients with neurologic diseases.
    Garcia-Monco JC; Coleman JL; Benach JL
    J Neuroimmunol; 2002 Aug; 129(1-2):216-23. PubMed ID: 12161038
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cleaved forms of the urokinase plasminogen activator receptor in plasma have diagnostic potential and predict postoperative survival in patients with ovarian cancer.
    Henic E; Borgfeldt C; Christensen IJ; Casslén B; Høyer-Hansen G
    Clin Cancer Res; 2008 Sep; 14(18):5785-93. PubMed ID: 18794088
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum level of soluble urokinase-type plasminogen activator receptor is a strong and independent predictor of survival in human immunodeficiency virus infection.
    Sidenius N; Sier CF; Ullum H; Pedersen BK; Lepri AC; Blasi F; Eugen-Olsen J
    Blood; 2000 Dec; 96(13):4091-5. PubMed ID: 11110678
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduced release of intact and cleaved urokinase receptor in stimulated whole-blood cultures from human immunodeficiency virus-1-infected patients.
    Ostrowski SR; Piironen T; Høyer-Hansen G; Gerstoft J; Pedersen BK; Ullum H
    Scand J Immunol; 2005 Apr; 61(4):347-56. PubMed ID: 15853918
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic importance of the soluble plasminogen activator receptor, suPAR, in plasma from rectal cancer patients.
    Fernebro E; Madsen RR; Fernö M; Brünner N; Bendahl P; Christensen IJ; Johnson A; Nilbert M
    Eur J Cancer; 2001 Mar; 37(4):486-91. PubMed ID: 11267858
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.